success survey

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

ONCOLOGY Staff

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

Novel Immunotherapy Achieves Responses/RFS in High-Risk, BCG-Unresponsive NMIBC

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

Related Content

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

ONCOLOGY Staff

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.